story of the week
Immune Checkpoint Inhibitor Therapy vs Targeted Therapy for Advanced Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
Clin. Cancer Res 2021 Nov 10;[EPub Ahead of Print], MM Regan, OA Jegede, CM Mantia, T Powles, L Werner, RJ Motzer, NM Tannir, CH Lee, Y Tomita, MH Voss, ER Plimack, TK Choueiri, BI Rini, HJ Hammers, B Escudier, L Albiges, S Huo, V Del Tejo, B Stwalley, MB Atkins, DF McDermottFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.